
The Peter Attia Drive · 12 Nov 2026 · 1 h 48 min
The GLP-1 era: what comes after semaglutide?
Listen on SpotifyOur summary
A deep conversation on how incretin-based peptides changed obesity research, and why triple agonists like retatrutide are drawing so much attention in current trials.
Key points
- Why combining GLP-1, GIP and glucagon receptor activity is being studied
- What the phase 2 data showed and what phase 3 still needs to answer
- Open questions on muscle preservation and long-term follow-up
Exclusive for PeptideNews readers
Get exclusive access to a trusted source of RUO peptides
As a research site, we can give you access to a supplier that meets the standards we write about.
- 60-day money-back guarantee
- Temperature-protected shipping
- Produced in the EU
- Third-party lab tested
- Traceable testing
- 99% purity
- Delivery in 2–5 days across the EU
For research use only (RUO). Not for human consumption.